Ireland
--:--IST
Recruiting Not applicable

Dexmedetomidine Versus Lidocaine Infusions as Adjuvants to General Anesthesia for Chronic Pain Management After Mastectomy

NCT06910644 · tracked via the Priya Life Science Egypt tracker
Phase
Not applicable
Started
2025-04-05
Last updated
2025-04-08

Condition(s) studied

DexmedetomidineLidocaineInfusionAdjuvantsGeneral AnesthesiaChronic PainMastectomy

Investigational drug(s) / intervention(s)

Dexmedetomidine →Lidocaine →Isotonic saline

Dexmedetomidine: Patients will receive 1 μg/kg of intravenous dexmedetomidine over 10 min followed by an intravenous infusion of 0.5 μg/kg/h.

Lidocaine: Patients will receive a bolus of intravenous lidocaine 1.5mg/kg over 10 min followed by a continuous infusion of lidocaine 1.5mg/kg/h.

Isotonic saline: Patients will receive intravenous isotonic saline 0.9% in the same volume and manner as the study drugs.

Study summary

This study aims to compare dexmedetomidine and lidocaine infusions as adjuvants to general anesthesia for chronic pain management after mastectomy.

Eligibility

Sex
FEMALE
Min age
18 Years
Max age
75 Years
Healthy volunteers
No
Inclusion Criteria: * Age from 18 to 75 years. * American Society of Anesthesiologists (ASA) physical status II. * Scheduled for mastectomy with axillary dissection (either modified radical mastectomy with or without latissimus dorsi flap or conservative breast surgery) due to breast cancer. Exclusion Criteria: * Patient refusal. * Known allergy to any of the study drugs. * Those with hepatic or renal insufficiency. * Patients who are running regularly on B blockers. * α2 adrenergic agonists and sedatives. * Psychoactive medications.

Primary outcome measure(s)

  • Incidence of the chronic pain — 6 months postoperatively
    Incidence of the chronic pain will be recorded.

Trial sites (1)

FacilityCityRegionStatus
Cairo University Cairo Egypt Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06910644 on ClinicalTrials.gov ↗ ← All trials in Egypt